Apr 13, 2021 11:05am Kyverna is working on T-cell therapies for autoimmune diseases that could be safer and last longer than current options. (Paul Bright / Unsplash)
James Chung (Kyverna Therapeutics)
James Chung, a longtime Amgen executive who led global clinical development for autoimmune drug Enbrel, has a new gig. He joins Kyverna Therapeutics as chief medical officer as the company sets its sights on the clinic.
Chung, who holds an M.D. and a Ph.D., arrives after more than 16 years at Amgen. He was most recently head of inflammation and neuroscience in Amgen’s global medical organization and global development leader for Enbrel, a drug approved for several autoimmune diseases including rheumatoid arthritis, plaque psoriasis and ankylosing spondylitis.